In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

A common variant in CCDC93 protects against myocardial infarction and cardiovascular mortality by regulating endosomal trafficking of low-density lipoprotein receptor

Paper commented by the ESC WG on Cellular Biology of the Heart

Basic Science - Cardiac Diseases - Ischemia, Infarction, Cardioprotection

Increasing low-density lipoprotein receptor (LDLR) re-cycling by blocking the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces LDL cholesterol and subsequently cardiovascular morbiditiy and mortality. However, other proteins are also involved in LDLR cycling and here the authors demonstrate a role for CCDC93. CCDC93 p.Pro228Leu was  dose-dependently associated with lower LDL cholesterol and lower risk of myocardial infarction and cardiovascular mortality. The variant of CCDC93 was shown to increase CCDC93 protein stability, and overexpression of human CCDC93 decreased plasma LDL cholesterol in mice. Conversely, CCDC93 ablation reduces LDL uptake as a result of reduced LDLR levels at the cell membrane. Thus, a new target protein involved in cholesterol metabolism affecting cardiovascular morbidity and mortality have been identified.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.